Skip directly to content

Referencias


1. MacFarlane LA, Todd La. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2014;17:359-368.
2. Barclay N, Tarallo M. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. PMS78. Value Health. 2013;16:A568.
3. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
4. Smolen JS, Landewé R. EULAR recommendations for the management of rheumatoid arthritis - 2016 Update. EULAR Congress 2016. Available at: http://eular.org. Accessed June 28, 2016.
5. van Vollenhoven RF, Fleischmann R, Cohen S, et al. For the ORAL Standard investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508-519.
6. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(suppl):1-18.
7. Tofacitinib for the treatment of rheumatoid arthritis. Advisory committee briefing document. May 9, 2012; http://www.fda.gov. Accessed November 20, 2014.
8. Bergrath E, Gerber R, Gruben D, et al. Tofacitinib versus biologic treatment in moderate to severe rheumatoid arthritis patients who have had an inadequate response to non biologic DMARDs: systematic literature review and network meta-analysis. Ann Rheum Diseases: 2016;75(Supp2):726.
9. Lee EB, Fleischmann R, Hall S, et al. For the ORAL Start investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377-2386.
10. van der Heijde D, Tanaka Y, Fleischmann R, et al. And the ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3)559-570.
11. Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015;17:307.
12. Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford). 2016;55:1031-1041.
13. Fleischmann R, Kremer J, Cush J, et al. For the ORAL Solo investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;267(6):495-507.
14. Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis. Ann Intern Med. 2013;159:253-261.
15. Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis. Ann Intern Med. 2013;159(4)(suppl):1-48.
16. Lee BE, Fleischman R, Hall S, et al. Supplement to tofacitinib versus methotrexate in rheumatoid arthritis. N Eng J Med. 2014;370:2377-2386.
17. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451-460.
18. Wollenhaupt J, Silverfield J, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years. Poster presented at: Annual Meeting of the American College of Rheumatology/Annual Meeting of the Association of Rheumatology Health Professionals; November 6-11, 2015; San Francisco, CA, USA.


Clic aquí para ver el Documento Local del Producto
PERXEL9017140-08/17
R.S.: Xeljanz 5 mg tabletas: EE-00112
Material Exclusivo para Profesionales de la Salud.